Pfizer punts $6.7 billion on expanding immuno-inflam portfolio

13 December 2021
pfizer_colour_new_large

US pharma giant Pfizer (NYSE: PFE) today revealed it has entered into a definitive agreement to acquire Arena Pharmaceuticals (Nasdaq: ARNA), a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion. The boards of directors of both companies have unanimously approved the transaction. News of the deal pushed Arena’s shares up 96% to $98.00 in pre-market trading this morning.

This is the third M&A deal for Pfizer so far this year. with the company having acquired Canada’s Trillium Therapeutics for $2.26 billion, and USA-based Amplyx Pharma for an undisclosed amount. Pfizer expects to finance the latest transaction with existing cash on hand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical